Top Page
Singular Health Group Ltd
(Sydney:SHG)
Singular Health Group Ltd (SHG) vs. iShares MSCI Australia ETF (EWA)
Singular Health Group Ltd Business Overview & Revenue Model
Singular Health Group Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 557.61K | 557.61K | 934.07K | 28.12K | 54.03K | 193.64K |
| Gross Profit | -86.22K | -86.22K | 516.36K | -3.58M | -2.11M | -1.62M |
| EBITDA | -7.46M | -6.27M | -2.58M | -4.52M | -5.65M | -2.86M |
| Net Income | -6.38M | -6.38M | -4.92M | -5.39M | -5.99M | -4.46M |
Balance Sheet | ||||||
| Total Assets | 14.21M | 14.21M | 2.35M | 3.00M | 2.14M | 5.43M |
| Cash, Cash Equivalents and Short-Term Investments | 13.68M | 13.68M | 1.45M | 691.51K | 1.14M | 4.14M |
| Total Debt | 0.00 | 0.00 | 218.45K | 2.51M | 85.66K | 147.59K |
| Total Liabilities | 1.11M | 1.11M | 909.59K | 2.94M | 391.50K | 345.10K |
| Stockholders Equity | 13.10M | 13.10M | 1.44M | 61.89K | 1.75M | 5.08M |
Cash Flow | ||||||
| Free Cash Flow | -2.37M | -2.37M | -2.51M | -2.49M | -2.92M | -2.22M |
| Operating Cash Flow | -2.34M | -2.34M | -2.44M | -2.46M | -2.91M | -1.91M |
| Investing Cash Flow | 88.14K | 88.14K | -3.56K | -635.21K | -17.12K | -610.57K |
| Financing Cash Flow | 14.48M | 14.48M | 3.21M | 2.65M | -69.25K | 6.52M |
Singular Health Group Ltd Technical Analysis
Singular Health Group Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | AU$154.44M | 95.83 | 1.89% | ― | 10.06% | ― | |
54 Neutral | AU$144.51M | -22.67 | -12.35% | ― | 15.99% | 22.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$59.57M | -9.15 | -13.83% | ― | 3.61% | -17.03% | |
43 Neutral | AU$78.49M | -11.45 | ― | ― | ― | ― | |
42 Neutral | AU$59.04M | -6.29 | -8647.54% | ― | 25.98% | 22.10% |
Singular Health Group Ltd Corporate Events
Singular Health Group Ltd has announced the cessation of 5,000,000 listed options (ASX code SHGAY) that expired unexercised on 23 December 2025, each carrying an exercise price of A$0.40. The lapse of these options slightly simplifies the company’s capital structure by removing a class of potential dilutive securities, which may alter future capital-raising flexibility but has no immediate cash impact, and signals that current market conditions did not support conversion at the exercise price.
The most recent analyst rating on (AU:SHG) stock is a Hold with a A$0.26 price target. To see the full list of analyst forecasts on Singular Health Group Ltd stock, see the AU:SHG Stock Forecast page.
Singular Health Group Ltd has notified the ASX that a tranche of listed options has lapsed, reducing its pool of potential dilutive securities. The company confirmed that 2,030,000 options exercisable at A$0.30 and expiring on 20 December 2025 ceased to exist unexercised, a routine capital management event that slightly streamlines its issued capital structure and may marginally lessen prospective dilution for existing shareholders.
The most recent analyst rating on (AU:SHG) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Singular Health Group Ltd stock, see the AU:SHG Stock Forecast page.
Singular Health Group Limited has disclosed a change in director Denning Chong’s relevant interests in the company’s securities, involving a mix of direct and indirect holdings across ordinary shares, unlisted options, and performance rights held through several controlled entities. As part of his managing director remuneration package and following shareholder approval at the company’s 2025 annual general meeting, Chong has been granted 6 million new unlisted incentive options exercisable at $0.55 and expiring on 30 November 2029, which are subject to various vesting conditions; the award increases his potential equity exposure and further aligns executive incentives with long-term shareholder outcomes.
The most recent analyst rating on (AU:SHG) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Singular Health Group Ltd stock, see the AU:SHG Stock Forecast page.
Singular Health Group Ltd, listed on the ASX under the code SHG, has notified the market of a new issuance of unquoted equity securities in the form of options. The company has issued 6 million unlisted options, each with an exercise price of $0.55 and an expiry date of 30 November 2029, dated 18 December 2025, signalling a move to potentially raise additional capital in the future and further align incentives for stakeholders through long-dated option-based compensation or financing structures.
The most recent analyst rating on (AU:SHG) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Singular Health Group Ltd stock, see the AU:SHG Stock Forecast page.
Singular Health Group Ltd announced the issuance of 900,000 fully paid ordinary shares following the exercise of unlisted options, raising $135,000. This move reflects the company’s ongoing efforts to strengthen its financial position and support its mission of advancing medical technology solutions. The announcement, authorized by the Board of Directors, indicates compliance with relevant provisions of the Corporations Act, ensuring transparency and adherence to regulatory standards.
The most recent analyst rating on (AU:SHG) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Singular Health Group Ltd stock, see the AU:SHG Stock Forecast page.
Singular Health Group Ltd has announced the quotation of 900,000 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move, resulting from the exercise of options or conversion of other securities, is part of the company’s ongoing efforts to enhance its market presence and operational capacity.
The most recent analyst rating on (AU:SHG) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Singular Health Group Ltd stock, see the AU:SHG Stock Forecast page.
Singular Health Group Ltd has submitted a 510(k) premarket notification to the FDA for its 3DICOM MD™ Cloud, an advanced version of their existing 3DICOM MD™ Viewer. This new platform enhances imaging capabilities by including X-ray and ultrasound modalities and offers a cloud-native solution for medical image management and collaboration. The submission marks a significant step in Singular Health’s regulatory journey, aiming to expand its U.S. market presence and support its strategy to increase recurring revenue through healthcare provider adoption. Achieving FDA clearance would validate the platform’s cloud-based architecture and strengthen its business case by reducing the need for complex desktop installations, thereby improving usability and access to 3D medical imaging.
The most recent analyst rating on (AU:SHG) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Singular Health Group Ltd stock, see the AU:SHG Stock Forecast page.
Singular Health Group Ltd has announced the issuance of 509,091 fully paid ordinary shares following the exercise of unlisted options, raising $50,909.10. This move signifies the company’s ongoing efforts to strengthen its financial position and enhance its market operations, potentially benefiting stakeholders by increasing the liquidity and visibility of its shares.
The most recent analyst rating on (AU:SHG) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Singular Health Group Ltd stock, see the AU:SHG Stock Forecast page.
Singular Health Group Ltd has announced the issuance of 509,091 ordinary fully paid securities, which will be quoted on the ASX. This move is part of the company’s strategy to leverage convertible securities, potentially impacting its market positioning by increasing liquidity and investor interest.
The most recent analyst rating on (AU:SHG) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Singular Health Group Ltd stock, see the AU:SHG Stock Forecast page.
Singular Health Group Ltd has released a presentation at the Canaccord Drug and Device Conference in Noosa, outlining the speculative and high-risk nature of investing in the company due to its startup status. The presentation emphasizes that the information provided is for informational purposes only and does not constitute an offer or financial advice. Investors are urged to consider their own financial situations and seek appropriate advice before making investment decisions.
The most recent analyst rating on (AU:SHG) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Singular Health Group Ltd stock, see the AU:SHG Stock Forecast page.
Singular Health Group Ltd has made significant strides in its U.S. market expansion during the September 2025 quarter, marked by the deployment of 250 licenses of its 3DICOM™ MD product under a contract with Provider Network Solution (PNS). The company anticipates substantial cost savings for PNS and is poised for further contract expansion. Additionally, Singular Health is engaging with major U.S. healthcare organizations and federal agencies to integrate its solutions into broader healthcare programs, supported by a strong financial position and the establishment of a U.S. subsidiary.
The most recent analyst rating on (AU:SHG) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Singular Health Group Ltd stock, see the AU:SHG Stock Forecast page.
Singular Health Group Ltd has announced its 2025 Annual General Meeting, scheduled for November 19, 2025, in Perth, Western Australia. Shareholders are encouraged to participate either in person or by proxy, with relevant documents available online. This meeting is crucial for shareholders to exercise their voting rights and engage with the company’s strategic direction, reflecting Singular Health’s commitment to transparent corporate governance.
The most recent analyst rating on (AU:SHG) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Singular Health Group Ltd stock, see the AU:SHG Stock Forecast page.